Long-Term Therapy with Adefovir Dipivoxil (Hepsera) for HBeAg-negative Chronic Hepatitis B

Treatment with adefovir dipivoxil (Hepsera) for 48 weeks resulted in histologic, virologic, and biochemical improvement in patients with hepatitis B e antigen (HBeAg)–negative chronic hepatitis B. In the current study, researchers evaluated the effect of continued therapy as compared with cessation of therapy.

One hundred eighty-five HBeAg-negative patients with chronic hepatitis B were assigned to receive 10 mg of adefovir dipivoxil or placebo once daily for 48 weeks (ratio, 2:1). After week 48, patients receiving adefovir dipivoxil were again randomly assigned either to receive an additional 48 weeks of the drug or to switch to placebo.

Patients originally assigned to placebo were switched to adefovir dipivoxil. Patients treated with adefovir dipivoxil during weeks 49 through 96 were subsequently offered continued therapy.

The primary end points were changes in hepatitis B virus (HBV) DNA and alanine aminotransferase levels.

Results

·  Treatment with adefovir dipivoxil resulted in a median decrease in serum HBV DNA of 3.47 log copies per milliliter (on a base-10 scale) at 96 weeks and 3.63 log copies per milliliter at 144 weeks.

·  HBV DNA levels were less than 1000 copies per milliliter in 71 percent of patients at week 96 and 79 percent at week 144.

·  In the majority of patients who were switched from adefovir dipivoxil to placebo, the benefit of treatment was lost (median change in HBV DNA levels from baseline, –1.09 log copies per milliliter; only 8 percent of patients had levels below 1000 copies per milliliter at week 96).

·  Side effects during weeks 49 through 144 were similar to those during the initial 48 weeks.

·  Resistance mutations rtN236T and rtA181V were identified in 5.9 percent of patients after 144 weeks.

Conclusions

Based on these findings, the authors conclude, “In patients with HBeAg-negative chronic hepatitis B, the benefits achieved from 48 weeks of adefovir dipivoxil were lost when treatment was discontinued. In patients treated for 144 weeks, benefits were maintained, with infrequent emergence of viral resistance.”

07/01/05

Reference
S J Hadziyannis and others (for the Adefovir Dipivoxil 438 Study Group). Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B. The New England Journal of Medicine 352(26): 2673-2681. June 30, 2005.

Articles on Hepsera

Resistance to Adefovir Dipivoxil (Hepsera) Can Be Associated with Significant Virologic Breakthough and Fatal Hepatic Decompensation - 5/27/05

Adefovir Dipivoxil Demonstrates Sustained Efficacy in HBeAg-negative Chronic Hepatitis B Patients - 5/23/05

Increasing Serologic, Virologic and Biochemical Response Over Time to Adefovir Dipivoxil (ADV) 10 mg in HBeAg+ Chronic Hepatitis B Patients - 5/23/05

Pegylated Interferon Alfa-2b (PegIntron) and Adefovir Dipivoxil (Hepsera) Combination Therapy in Chronic Hepatitis B (CHB) Patients Leads to a Strong Suppression of cccDNA and High Rates of HBe and HBs Seroconversion - 5/16/05

Predictors of a Poor Outcome in Patients Treated with Adefovir for Reactivation of Chronic Hepatitis B Due to Lamivudine-resistant HBV Mutants  - 5/09/05

Over Time, HBeAg-positive Chronic Hepatitis B Patients Experience Increasing Response to Adefovir - 5/02/05

Cost-Effectiveness of Two Oral Antiviral Therapies, Lamivudine and Adefovir Dipivoxil of HBe-Ag-Negative Chronic Hepatitis B
Poster Number 475. M Buti and others.

Adefovir Dipivoxil (ADV) Demonstrates Sustained Efficacy in HBeAg Negative Chronic Hepatitis B (CHB) Patients.
Poster Number 492. S Hadziyannis and others.

Clinical Profile of HBeAg- Chronic Hepatitis B Patients with Adefovir Dipivoxil Resistance Mutations.
Poster Number 508. S Lim and others.

Incidence and Predictors of Emergence of HBV Mutations Associated with ADV Resistance During 4 Years of ADV Therapy for Patients with Chronic Hepatitis B.
Oral 36. S Locarnini and others.

In Vitro Cross-Resistance Analysis of the HBV Polymerase Mutation A181V.
Poster Number 536. X Qi and others.

Adefovir Dipivoxil (ADV) is Effective for the Treatment of Patients with LAM-R Chronic Hepatitis B (CHB) in Cirrhotic and Elderly Patients.
Poster Number 545. F Zoulim and others.

Activity of Adefovir Dipivoxil Against All Patterns of Lamivudine-resistant Hepatitis B Virus - 2/16/05

Adefovir Dipivoxil as Rescue Therapy for Lamivudine-resistant Hepatitis B Post Liver Transplant - 1/24/05

The Lancet Publishes First Study Showing Peginterferon Alfa-2b Is Effective As Monotherapy In the Treatment of Chronic Hepatitis B: Press Announcement from the Erasmus Medical Center  - 01/07/05

Long-term Treatment with Adefovir Dipivoxil in Pre- and Post-Transplant Patients with Lamivudine-resistant HBV Results in Significant Improvement in Survival and Laboratory Functions - 12/06/04

HBV Mutants Associated with Clinical Resistance to Adefovir Cause Only Small Decreases in Drug Sensitivity - 12/06/04

Comparison of Adefovir and Tenofovir in the Treatment of Lamivudine-resistant Hepatitis B Virus Infection - 11/29/04

Treatment with Adefovir Dipivoxil 10 Mg Over 144 Weeks Results in Increasing HBeAg Loss and Seroconversion Rates and Continued Reductions in Serum HBV DNA and ALT Levels - 11/19/04

Continuous HBV DNA Suppression Seen in Patients with Lamivudine- resistant Hepatitis B During One Year of Therapy with Adefovir Dipivoxil - 11/17/04

144-Week Safety and Efficacy Data on Adefovir Dipivoxil in Chronic Hepatitis B - 11/03/04

Comparison of Adefovir Dipivoxil Plus Emtricitabine Combination Therapy vs Adefovir Alone in HBeAg(+) Chronic Hepatitis B 11/01/04

Cross-resistance Testing of Adefovir, Lamivudine, Telbivudine, Entecavir, and Other Anti-HBV Compounds Against 4 Major Mutational Patterns of Lamivudine-resistant
HBV 11/01/04

Lamivudine Prophylaxis with Adefovir Salvage Therapy in Hepatitis B Patients Undergoing Liver Transplant Is More Cost Effective Than Combination Treatment with Lamivudine Plus HBIG 11/01/04

Current Treatments for Hepatitis B: An Overview - 10/25/04

Favorable Outcome of Adefovir-dipivoxil Treatment in Acute de novo Hepatitis B After Liver Transplantation 10/15/04

Renal Safety of Adefovir Dipivoxil in Patients with Chronic Hepatitis B - 09/15/04

Adefovir Dipivoxil and Tenofovir Are Highly Efficacious Therapies in HBV Patients with Lamivudine Resistance  - 08/13/04

Long-term Treatment with Adefovir Dipivoxil 10 mg (ADV) in Patients with Lamivudine-resistant (LAM-R) HBV and HIV Co-infection Results in Significant and Sustained Clinical Improvement - 07/21/04

Lack of Systemic or Renal Drug Interactions of Tenofovir DF with Ribavirin or Adefovir Dipivoxil. - 07/21/04

Significant and Sustained Efficacy of Adefovir Dipivoxil after Four Years of Treatment in Chronic Hepatitis B Patients with Lamivudine-Resistant HBV and HIV Co-Infection 05/17/04

Salvage Therapy with Adefovir Is Cost-Effective in Chronic Hepatitis B 05/17/04

Adefovir Therapy Reduces Hepatitis B Surface Antigen (HBsAg) Levels in Chronic HBV Patients 05/17/04

After 5 Months of Therapy, Adefovir Dipivoxil Results in a Significant Reduction of HBV DNA in 72% of Patients with Lamivudine Resistance 04/28/04

Index of All Hepatitis B Articles by Topic   A to Z